Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age

Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults ≥50 years of age was immunogenic and well tolerated.

Authors

Spyros Chalkias (ORCID: https://orcid.org/0000-0002-6254-1158)
Ulrike K. Buchwald (ORCID: https://orcid.org/0000-0002-6671-0115)
Gretchen Tamms
Morgan Johnson (ORCID: https://orcid.org/0000-0002-2081-6176)
Tulin Shekar
Enrique Pelayo (ORCID: https://orcid.org/0000-0003-3656-8098)
Aaron S. Weinberg
Natalie Banniettis
Alejandra Esteves-Jaramillo (ORCID: https://orcid.org/0000-0002-6165-197X)
Lori Good
Tina M. Sterling
Tosin Omole (ORCID: https://orcid.org/0000-0002-8047-266X)
Zelalem Endale

Institutions

Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
Moderna Therapeutics (United States) (US)
Carbon180 (US)
Advanced Medical Research Institute (US)

Publication Details

Journal: Vaccines
Published: 2025-02-15
DOI: https://doi.org/10.3390/vaccines13020192
Citations: 3
Primary Topic: Pneumonia and Respiratory Infections
Type: article
Field-Weighted Citation Impact: 4.06

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age

Spyros Chalkias, Ulrike K. Buchwald, Gretchen Tamms, Morgan Johnson et al.

Feb 15, 2025

3 citations

Vaccines

Pneumonia and Respiratory Infections

4.06

article

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age

Spyros Chalkias, Ulrike K. Buchwald, Gretchen Tamms, Morgan Johnson, Tulin Shekar, Enrique Pelayo, Aaron S. Weinberg, Natalie Banniettis, Alejandra Esteves-Jaramillo, Lori Good, Tina M. Sterling, Tosin Omole, Zelalem Endale

February 15, 2025article en

3 citations

Abstract

Co-administration of mRNA-1273 with PPSV23 or PCV15 in healthy adults ≥50 years of age was immunogenic and well tolerated.

VaccinesVol. 13(2)

Merck & Co., Inc., Rahway, NJ, USA (United States) (US), Moderna Therapeutics (United States) (US), Carbon180 (US), Advanced Medical Research Institute (US)

Openalex Percentile: Top 7%

Pneumonia and Respiratory Infections

4.06

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Safety, Tolerability, and Immunogenicity of the Pneumococcal Vaccines PPSV23 or PCV15 Co-Administered with a Booster Dose of mRNA-1273 SARS-CoV-2 Vaccine in Healthy Adults ≥50 Years of Age — Spyros Chalkias, Ulrike K. Buchwald, et al. · Vaccines (2025) | TGRS Research Map | TGRS